問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

黃美鳳Huang, mei feng
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

篩選

List

14Cases

2026-07-01 - 2029-05-31

Phase III

Active
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
  • Condition/Disease

    Depressive Disorder, Treatment-Resistant

  • Test Drug

    鼻用噴液劑 鼻用噴液劑

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease
  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    錠劑

Participate Sites
9Sites

Not yet recruiting9Sites

2017-12-15 - 2020-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-12-01 - 2014-04-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)
  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-01-05 - 2013-06-30

Phase III

A phase 3, multicenter, randomized, double-blind, placebo-controlled Trial of Fixed-dose OPC-34712 (4,2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia
  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

2012-03-30 - 2014-06-30

Phase III

A phase 3, Multicenter, Open-label trial to evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia
  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

1 2